| Biomarker ID | 806 |
| PMID | 22077694 |
| Year | 2011 |
| Biomarker | Methylation of GSTP1 + APC |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (GSTP1): Biological oxidations, Metapathway biotransformation, Pathways in cancer, T cell receptor regulation of apoptosis, Metabolism Pathways include (APC): Pathways in cancer, Signal transduction, Irinotecan pathway, Actin cytoskeleton regulation, Apoptosis |
| Experiment | negative histology followed by a positive biopsy more than 24 months later |
| Type of Biomarker | Prognostic |
| Cohort | 86 men with an initial histologically negative prostate biopsy were chosen for repeat biopsy |
| Senstivity | (group 1 + Group 3) = 0.95 (0.76–1.00) ; (group 1 + Group 2) = 1.00 (0.72–1.00) |
| Specificity | (group 1 + group 3) : 0.38 (0.27–0.51) ; (group 1 + Group 2) = 0.45 (0.31–0.60) |
| AUC | NA |
| Accuracy | (group 1 + group 3) : [TP: 20 FN: 1 TN: 25 FP: 40]; (group 1 + Group 2) = [TP: 11 FN: 0 TN: 22 FP: 27 ] |
| Level Of Significance | NA |
| Method Used | Quantitave Methylation Specific PCR |
| Clinical | No |
| Remarks | Patients were divided into 3 risk groups on the basis of cancer incidence. Cancer incidence (determined by repeat biopsy) was 24% (21/86); within Groups 1, 2 and 3 the incidence was 14%, 21%, and 39%, respectively. Group 1: suspicious DRE or high-risk PSA level (PSA ≥ 8.0 ng/mL and prostate volume <50.0 mL, PSA density ≥0.2 ng/mL/cm , or percent free PSA (%fPSA) ≤ 10.0); Group 2: high-grade prostatic intraepithelial neoplasia (HGPIN); Group 3: atypical small acinar proliferation (ASAP) on initial biopsy. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | GSTP1, APC |